| Literature DB >> 29882886 |
Vasiliki Paraskevopoulou1, Franco H Falcone2.
Abstract
Since the introduction of recombinant protein expression in the second half of the 1970s, the growth of the biopharmaceutical field has been rapid and protein therapeutics has come to the foreground. Biophysical and structural characterisation of recombinant proteins is the essential prerequisite for their successful development and commercialisation as therapeutics. Despite the challenges, including low protein solubility and inclusion body formation, prokaryotic host systems and particularly Escherichia coli, remain the system of choice for the initial attempt of production of previously unexpressed proteins. Several different approaches have been adopted, including optimisation of growth conditions, expression in the periplasmic space of the bacterial host or co-expression of molecular chaperones, to assist correct protein folding. A very commonly employed approach is also the use of protein fusion tags that enhance protein solubility. Here, a range of experimentally tested peptide tags, which present specific advantages compared to protein fusion tags and the concluding remarks of these experiments are reviewed. Finally, a concept to design solubility-enhancing peptide tags based on a protein's pI is suggested.Entities:
Keywords: peptide tag; polyanionic; polycationic; protein fusion tag; protein solubility; recombinant protein expression
Year: 2018 PMID: 29882886 PMCID: PMC6027335 DOI: 10.3390/microorganisms6020047
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Suggested mechanism of native protein folding and association of intermediate, partially folded protein molecules, bearing native-like secondary structures, leading to inclusion body formation.
Protein fusion tags for solubility enhancement during recombinant protein production.
| Name | Full Name | Size (kDa) | Reference |
|---|---|---|---|
| GST | Glutathione- | 26 | Smith et al., 1988 [ |
| MBP | Maltose-binding protein | 42.5 | Maina et al., 1988 [ |
| UB | Ubiquitin | ~9 | Butt et al., 1989 [ |
| Trx | Thioredoxin | 11.7 | LaVallie et al., 1993 [ |
| Z-tag/ZZ-tag | IgG-binding domain from protein A | 15.5/31 | Samuelsson et al., 1994 [ |
| GB1 | Immunoglobulin-binding domain of protein G | 6.2 | Huth et al., 1997 [ |
| DsbA | Disulphide isomerase I | 21.1 | Collins-Racie et al., 1998 [ |
| DsbAmut | Zhang et al., 1998 [ | ||
| NusA | N-utilization substance A | 55 | Davis et al., 1999 [ |
| IF2 domain I (or | Initiation factor 2 | Sorensen et al., 2003 [ | |
| CaBP | Calcium binding protein | Reddi et al., 2002 [ | |
| SUMO | Small ubiquitin-related modifier | 31 | Malakhov et al., 2004 [ |
| FTN-H | Ferritin heavy-chain | Ahn et al., 2005 [ | |
| Skp | Seventeen kilodalton protein | 17 | Chatterjee et al., 2006 [ |
| T7PK | T7 protein kinase | 4.5 | Chatterjee et al., 2006 [ |
| Ecotin | 16 | Malik et al., 2006 [ | |
| RpoA | RNA Polymerase α-subunit | 39.5 | Ahn et al., 2007 [ |
| PotD | Spermidine/putrescine-binding periplasmic protein | 39.8 | Han et al., 2007 [ |
| Crr | Glucose-specific phosphotransferase (PTS) enzyme IIA component | 20 | Han et al., 2007 [ |
| Tsf | Elongation factor Ts | 30.6 | Han et al., 2007 [ |
| SlyD | Aggregation-resistant protein | 22.2 | Han et al., 2007 [ |
| msyB | Acidic protein | 14 | Su et al., 2007 [ |
| RpoS | RNA polymerase sigma factor | 39 | Park et al., 2008 [ |
| yjgD | 15 | Zou et al., 2008 [ | |
| rpoD | σ 70 factor of RNA polymerase | 20 | Zou et al., 2008 [ |
| HaloTag7 | Inactive derivative of DhaA, a bacterial haloalkane dehalogenase | 34 | Ohana et al., 2009 [ |
| Superfolder green fluorescent protein | Wu et al., 2009 [ | ||
| Mocr | Monomeric bacteriophage T7 0.3 | 16.7 | DelProposto et al., 2009 [ |
| SNUT | Solubility eNhancing Ubiquitous Tag | 19 | Caswell et al., 2010 [ |
| EspA | 25 | Cheng et al., 2010 [ | |
| ArsC | Arsenate reductase | 16 | Song et al., 2011 [ |
| BLA | AmpC-type β-lactamase | Tokunaga et al., 2010 [ | |
| Entity of | 28 | Hansted et al., 2011 [ | |
| Fh8 | 8 | Costa et al., 2014 [ | |
| SmbP | Small metal-binding protein | 9.9 | Vargas-Cortez et al., 2016 [ |
| Ffu | β-fructofuranosidase truncations | 17.7–29.5 | Cheng et al., 2017 [ |
| TDX | Tetracopeptide domain-containing thioredoxin | 35 | Xiao et al., 2018 [ |
| HE-MBP(Pyr) | Truncated maltotriose-binding protein with modified histidine tag | Han et al., 2018 [ |
Polyionic or polar peptide tags assessed for their solubility enhancement effect during recombinant protein expression.
| Name | pI | Size (kDa) | Reference |
|---|---|---|---|
| (Arg)1–5 | 10.00–12.62 | 0.174–0.799 | Kato et al., 2007 [ |
| (Arg)5 | 12.62 | 0.799 | Islam et al., 2015 [ |
| (Arg)10 | 12.95 | 1.6 | Jung H-J et al., 2011 [ |
| (Arg-Gly-Gly)3-Gly | 12.30 | 0.886 | Englebretsen et al., 1999 [ |
| Poly(Arg) | Smith et al., 1984 [ | ||
| (Gly-Arg)3-(Arg)3 | 12.91 | 1.5 | Kalpana et al., 2018 [ |
| (Gly-Arg)4 | 12.48 | 0.871 | Englebretsen et al., 1996 [ |
| Gly-(Arg)5 | 12.62 | 0.856 | Sato et al., 2005 [ |
| Gly(Arg-Gly-Gly)3 | 12.30 | 0.886 | Choma et al., 1998 [ |
| (Gly)2-(Arg)2-Gly-Arg | 12.30 | 0.658 | Gao et al., 2017 |
| (Gly)2(Lys)4 | 10.47 | 0.645 | Park et al., 2003 [ |
| (Lys)1–5 | 8.88–10.61 | 0.146–0.659 | Kato et al., 2007 [ |
| (Lys)2 | 10.00 | 0.274 | Wang et al., 1999 [ |
| (Lys)3 | 10.28 | 0.402 | Bianchi et al., 1994 [ |
| (Lys)5 | 10.61 | 0.659 | Islam et al., 2015 [ |
| (Lys)6 | 10.70 | 0.787 | Hage et al., 2015 [ |
| (Lys)10 | 10.94 | 1.3 | Englebretsen et al., 1999 [ |
| (Asp)5 | 3.34 | 0.593 | Kim et al., 2015 [ |
| (Asp)5 |
|
| Islam et al., 2015 [ |
| [Gly-(Asp)3]3 | 3.16 | 1.2 | Rathnayaka et al., 2011 [ |
| Negative peptide extensions (>−6) | Zhang et al., 2004 [ | ||
| (Asn)5 | 5.50 | 0.588 | Islam et al., 2015 [ |
Figure 2A method to enhance protein solubility during recombinant protein production is the introduction of solubility-enhancing tags (protein or peptide) in the recombinant plasmid. By having a few potential mechanisms of action, protein tags can cover a wider range of proteins in order to enhance solubility and most of them act simultaneously as solubility and purification tags. However, peptide tags are more versatile and smaller in size, which means their removal is not always essential, they do not pose a burden on the host system’s metabolism and they do not affect the target protein’s structure or function.